What we are researching
The purpose of this study is to find out how well the study medicine works in reducing the number of sickle cell pain crises in adolescents and adults living with sickle cell disease.
Who may participate
Each clinical trial has its own requirements for who can participate, often called eligibility criteria. Some of the key criteria for this study are listed here. Discuss these requirements with your study doctor to determine if you may be eligible to participate. Additional criteria for your doctor to review can be found here: NCT06612268.
Sickle Cell Disease
Have been diagnosed with sickle cell disease
Sickle Cell Pain Crises
Have 2 to 15 episodes of documented sickle cell pain crises within the 12 months before joining the study
Age
12+ years
Study Medicine
2 tablets by mouth daily
Number of study visits
About 20 visits over a period of about 26 months
What to expect
If your study doctor determines that you are eligible and you decide to participate, you will be enrolled into the study.
In the first year, you will be randomly assigned to take either the study medicine or placebo (which has no active medicine in it). During the second year, you will receive the study medicine, even if you were assigned to placebo in the first year.
Your participation is expected to last about 2 years and 2 months, with in-person visits about every 4 to 12 weeks. Visits may include physical exams, lab tests and questionnaires to monitor your health and safety.
Call 866-867-7178 or email clinicaltrials@novonordisk.com to learn more
about the study and find out whether there is a participating study site near you.
When you call, please reference study 7807 or HIBISCUS 2
You may also choose to discuss this clinical trial with your healthcare provider.